… of stroke and major bleeding in routine clinical practice [13]. … rivaroxaban treated patients
with non-valvular atrial fibrillation … evaluate the cost-effectiveness of the NOAC apixaban versus …

… is an increasingly important issue in clinical practice. … prevention of ischemic stroke in patients
with non-valvular AF (NVAF)… patients with stroke and AF treated with apixaban showed that …

… the Australian national general practice dataset over 5 years … 15%), patients treated with
apixaban that were exposed to … database including 91,330 patients with nonvalvular AF who …

… patients with non-valvular atrial fibrillation (NVAF) have broadened. Other DOACs including
rivaroxaban and apixaban … about the direct comparative effectiveness and safety within the …

… for non-vitamin K antagonist oral anticoagulants (NOACs). In … During the 6‑month follow-up,
patients treated with apixaban … that treatment with apixaban or warfarin in patients with AF on …

… or apixaban have been introduced as alternatives to vitamin K … and private practices enroll
NOAC-treated patients in this … to be licensed for VTE treatment in Germany. Therefore, the …

… describe the populations treated in clinical routine, to examine … in adult patients with
non-valvular atrial fibrillation (NVAF only), … an efficacious and safe DOAC treatment in daily …

… at risk of stroke because of non-valvular atrial fibrillation (… UK clinical practice there is a
significant proportion of people with … analysis found that apixaban was cost effective compared to …

… last date of data collection for their practice or the end of the study … an ‘on-treatment’ analysis
where patients were censored at … Efficacy and safety of apixaban compared with warfarin in …

… characterization of patients with AF to use in daily practice was … apixaban (n = 82) versus
VKA (n = 72) therapy in patients … Only 74.4% of these patients were treated with OAC after the …